Company Overview - Longeveron is a regenerative medicine company focused on cellular therapies for life-threatening and chronic aging-related conditions[1] - The company's lead product is Laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell (MSC) therapy derived from healthy young adult bone marrow[9] - Longeveron is targeting large U S markets with significant unmet medical needs, including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease (AD), and Aging-related Frailty (AF)[6] Clinical Pipeline and Regulatory Pathway - The company has positive initial results from 5 clinical trials across 3 indications and a well-established safety profile[6] - Laromestrocel has received 5 important FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease for HLHS, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track for AD[6] - A positive FDA Type C meeting for HLHS and an ongoing pivotal trial suggest a clear regulatory pathway to Biologics License Application (BLA)[6] - A positive FDA Type B meeting for AD and a planned single, pivotal Phase 2/3 clinical trial also indicate a potential BLA pathway[6] Market Opportunity - The U S market potential for HLHS is approximately $1 billion, for AD it is over $5 billion, and for Aging-related Frailty it is over $4 billion[6] - Alzheimer's Disease (AD) affects 6.9 million people in the U S [12] - Aging-related Frailty affects 8.1 million people in the U S [12] Financial Status - As of March 31, 2025, Longeveron had $14.3 million in cash and cash equivalents[57] - As of May 1, 2025, there were approximately 15.0 million shares of common stock outstanding, with approximately 6.8 million shares exercisable under outstanding warrants[58]

Dublin, April 29, 2025 (GLOBE NEWSWIRE) -- The "Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends - Forecast up to 2030" has been added to ResearchAndMarkets.com's offering. Cone rod dystrophy represents a group of genetic eye disorders impacting the retina's cone and rod cells. The market for treating this condition is witnessing substantial growth, projected to rise from a value of US$131.29 million in 2024 to US$177.59 million by 2030. This growth is ...

Wa'el Hashad Wa'el Hashad, CEO, Longeveron MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Fellow Shareholders, Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeve ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners Ram Selvaraju - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Longeveron 2024 and Full Year Financial Results Conference Call. At this time all participants are in a listen-only mode. ...